Measurement of DNA adducts in cells exposed to cisplatin.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Analytical Biochemistry

• Publication date

  2004-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.AB.2004.06.001PMID 15351281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA damage measured by liquid chromatography-mass spectrometry in mouse fibroblast cells exposed to oxidative stress.

  2003cited by this paper
• Mass spectrometry of cis-diamminedichloroplatinum(II) adducts with the dinucleosidemonophosphates d(ApG), d(GpG) and d(TpC) in an ion trap.

  2002cited by this paper
• Detection and Characterization of Formamido Lesions in DNA by Liquid Chromatography-Mass Spectrometry

  2002cited by this paper
• Focus on melanoma.

  2002cited by this paper
• Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry

  2001cited by this paper
• Is cisplatin-induced cell death always produced by apoptosis?

  2001cited by this paper
• In vitro studies on the mechanisms of oxaliplatin resistance

  2001cited by this paper
• Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair.

  2001cited by this paper
• BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.

  2000cited by this paper
• A 1H NMR study of the oligonucleotide binding of [(en)Pt(mu-dpzm)2Pt(en)]Cl4.

  2000cited by this paper
• Molecular mechanisms involved in cisplatin cytotoxicity

  2000cited by this paper
• The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

  1999cited by this paper
• Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells.

  1999cited by this paper
• Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours.

  1999cited by this paper
• The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.

  1998cited by this paper
• Enrichment for DNA mismatch repair‐deficient cells during treatment with cisplatin

  1998cited by this paper
• Cellular and molecular determinants of cisplatin resistance.

  1998cited by this paper
• Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.

  1997cited by this paper
• DNA Repair capacity and cisplatin sensitivity of human testis tumour cells

  1997cited by this paper
• In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.

  1997cited by this paper
• DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].

  1996cited by this paper
• Loss of DNA mismatch repair in acquired resistance to cisplatin.

  1996cited by this paper
• Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line*

  1996cited by this paper
• Capillary electrophoretic separation and laser-induced fluorescence detection of the major DNA adducts of cisplatin and carboplatin.

  1995cited by this paper
• High-performance liquid chromatographic—mass spectrometric analysis of cis-dichlorodiamineplatinum—DNA complexes using an ionspray interface

  1993cited by this paper
• Activation of programmed cell death by anticancer agents: cisplatin as a model system.

  1990cited by this paper
• Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

  1988cited by this paper
• Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts.

  1988cited by this paper
• Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA.

  1986cited by this paper
• Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.

  1985cited by this paper

• The multifaceted roles of mass spectrometric analysis in nucleic acids drug discovery and development.

  2021cites this paper
• Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct Formation.

  2021cites this paper
• A Reduced Graphene Oxide-based Electrochemical DNA Biosensor for the Detection of Interaction between Cisplatin and DNA based on Guanine and Adenine Oxidation Signals

  2017cites this paper
• The Analysis of Therapeutic Metal Complexes and Their Biomolecular Interactions

  2017cites this paper
• Quantification of Noble Metals in Biological and Environmental Samples

  2016cites this paper
• Analytical approaches to investigating metal-containing drugs.

  2015cites this paper
• Mass spectrometry analysis of nucleosides and nucleotides.

  2014cites this paper
• Mass Spectrometry Based Quantification of 1,3-Butadiene Induced DNA Adducts: Potential Biomarkers of Cancer Risk

  2014cites this paper
• Cisplatin intrastrand adducts sensitize DNA to base damage by hydrated electrons.

  2014cites this paper
• Measuring DNA damage and associated epigenetic changes genome-wide in cells following exposure to platinum analogue chemotherapeutic drugs

  2014cites this paper
• Hydrated electrons react with high specificity with cisplatin bound to single-stranded DNA.

  2013cites this paper
• Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

  2013cites this paper
• LC‐MS Bioanalysis of Platinum Drugs

  2013cites this paper
• Nuclease digestion and mass spectrometric characterization of oligodeoxyribonucleotides containing 1,2-GpG, 1,2-ApG, and 1,3-GpXpG cisplatin intrastrand cross-links.

  2013cites this paper
• Speciation of oxaliplatin adducts with DNA nucleotides.

  2011cites this paper
• Methods for the Determination of Platinum Group Elements in Environmental and Biological Materials: A Review

  2011cites this paper
• Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.

  2010cites this paper
• Quantitative methods for studying DNA interactions with chemotherapeutic cisplatin

  2010cites this paper
• Development of an ultra performance LC/MS method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts

  2009cites this paper
• Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts.

  2009cites this paper
• Quantitative profiling of in vivo generated cisplatin-DNA adducts using different isotope dilution strategies.

  2009cites this paper
• In vivo detection of DNA adducts induced by cisplatin using capillary HPLC–ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster

  2008cites this paper
• A study of oxaliplatin–nucleobase interactions using ion trap electrospray mass spectrometry

  2008cites this paper
• Development of a liquid chromatography-electrospray ionization tandem mass spectrometry method for detecting oxaliplatin-DNA intrastrand cross-links in biological samples.

  2007cites this paper
• Speciation studies of cis-platin adducts with DNA nucleotides via elemental specific detection (P and Pt) using liquid chromatography-inductively coupled plasma-mass spectrometry and structural characterization by electrospray mass spectrometry

  2006cites this paper